Affiliation:
1. Developmental Therapeutics Program, DCTD, National Cancer Institute, Bethesda, MD 20892, USA
Abstract
Abstract:
Antibody-drug conjugates offer the possibility of directing powerful cytotoxic agents to a
malignant tumor while sparing normal tissue. The challenge is to select an antibody target expressed
exclusively or at highly elevated levels on the surface of tumor cells and either not all or at low levels
on normal cells. The current review explores 78 targets that have been explored as antibody-drug conjugate
targets. Some of these targets have been abandoned, 9 or more are the targets of FDA-approved
drugs, and most remain active clinical interest. Antibody-drug conjugates require potent cytotoxic
drug payloads, several of these small molecules are discussed, as are the linkers between the protein
component and small molecule components of the conjugates. Finally, conclusions regarding the elements
for the successful antibody-drug conjugate are discussed.
Publisher
Bentham Science Publishers Ltd.
Subject
Cancer Research,Drug Discovery,Pharmacology,Oncology
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献